Advice
Following a resubmission.
Pioglitazone (Actos?) is accepted for restricted use within NHS Scotland as monotherapy for type 2 diabetes mellitus patients in whom consideration is otherwise being given to commencing insulin therapy. It is not recommended as monotherapy for any other group of patients.
It is one of two peroxisome proliferator-activated receptor-??agonists marketed in the UK for this indication. Its use should be restricted to patients who have already experienced severe hypoglycaemia or patients in whom metformin and sulphonylureas are contra-indicated or not tolerated.
Download detailed advice50KB (PDF)
Medicine details
- Medicine name:
- Pioglitazone (Actos®)
- SMC ID:
- 115/04
- Indication:
- Type 2 diabetes mellitus patients for whom metformin is inappropriate
- Pharmaceutical company
- Takeda UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Resubmission
- Status
- Restricted
- Date advice published
- 12 September 2005